{"id":390077,"date":"2021-03-17T00:00:00","date_gmt":"2021-03-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2020-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-18T23:22:33","modified_gmt":"2026-04-18T23:22:33","slug":"dlsfim0006-2020-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0006-2020-biopharma-psoriatic-arthritis-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>A series of launches are expected\u00a0to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors;\u00a0the impact of these launches will be strengthened by the increasing acceptance of biosimilars as alternatives to more-expensive branded therapies\u00a0and the novel mechanisms of action that are becoming\u00a0available. IL-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the sales of current therapies, especially the IL-12\/23 therapy ustekinumab. Targeted synthetic DMARDs, particularly JAK inhibitors, will fulfill the need for orally dosed therapies and increasingly capture early-line patient share.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less-expensive therapies?<\/li>\n<li>How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?<\/li>\n<li>What emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?<\/li>\n<li>What unmet needs remain to be treated in PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 24\u00a0country-specific interviews with thought-leading dermatologists and rheumatologists<strong>\u00a0<\/strong>supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2029, segmented by brands \/ biosimilars.<\/p>\n<p>Emerging therapies: Phase III\/PR: 5 drugs; Phase II: 2 drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390077","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390077\/revisions"}],"predecessor-version":[{"id":576435,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390077\/revisions\/576435"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}